Pathophysiology of C3G
Genetic and acquired abnormalities of the alternative pathway have been reported in patients with C3G and MPGN. These generally cause uncontrolled complement activation leading to complement deposition within the glomerulus.
Screening for a cause of uncontrolled complement activation should be considered in patients with a diagnosis of C3G. Screening for similar causes should also be undertaken in patients with MPGN once secondary causes have been excluded.